1. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors

   • Rebecca Liu
   • Duane A. Mitchell

   Review 16 September 2009 Pages: 183 - 193

   

2. Multimer technologies for detection and adoptive transfer of antigen-specific T cells

   • Rosaely Casalegno-Garduño
   • Anita Schmitt
   • Michael Schmitt

   Review 22 October 2009 Pages: 195 - 202

   

3. Loci controlling lymphocyte production of interferon γ after alloantigen stimulation in vitro and their co-localization with genes controlling lymphocyte infiltration of tumors and tumor susceptibility

   • Marie Lipoldová
   • Helena Havelková
   • Peter Demant

   Original Article Open access 05 August 2009 Pages: 203 - 213

   

4. Systemic dysregulation of CEACAM1 in melanoma patients

   • Gal Markel
   • Rona Ortenberg
   • Jacob Schachter

   Original Article 25 July 2009 Pages: 215 - 230

   

5. Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)

   • Cecilie Totland
   • Geir Bredholt
   • Christian A. Vedeler

   Original Article 14 August 2009 Pages: 231 - 237

   

6. Assessment of the pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE

   • Hui Wang
   • Jing Shi
   • Dechao Yu

   Original Article 25 July 2009 Pages: 239 - 246

   

7. Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin

   • Wei Luo
   • Wang-Jun Liao
   • Xiao-Ning Wang

   Original Article 04 August 2009 Pages: 247 - 256

   

8. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

   • Pina M. Cardarelli
   • Chetana Rao-Naik
   • David J. King

   Original Article 06 August 2009 Pages: 257 - 265

   

9. Tumors induce the formation of suppressor endothelial cells in vivo

   • Jennifer Konopa Mulligan
   • M. Rita I. Young

   Original Article 09 August 2009 Pages: 267 - 277

   

10. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy

    • Xia Wu
    • Qin-Mei Feng
    • Wen Di

    Original Article 30 August 2009 Pages: 279 - 291

    

11. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

    • Anda M. Vlad
    • Raluca A. Budiu
    • Robert P. Edwards

    Original Article 19 August 2009 Pages: 293 - 301

    

12. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

    • Marna G. Bouwhuis
    • Andreas Gast
    • Rajiv Kumar

    Original Article Open access 12 August 2009 Pages: 303 - 312

    

13. Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells

    • Bo Li
    • Zhang Lei
    • Bo Huang

    Original Article 13 August 2009 Pages: 313 - 321

    

14. Immune impairment in patients with terminal cancers: influence of cancer treatments and cytomegalovirus infection

    • I-Hsuan Chen
    • Yuen-Liang Lai
    • Yen-Ta Lu

    Original Article 15 August 2009 Pages: 323 - 334

    

15. Impact of Cytomegalovirus infection on immune signatures in cancer patients

    • Evelyna Derhovanessian

    Letter to the editor 17 September 2009 Pages: 335 - 336

16. Response to Dr Derhovanessian “Impact of cytomegalovirus infection on immune signatures in cancer patients”

    • Yen-Ta Lu
    • I-Hsuan Chen

    Letter to the editor 04 November 2009 Pages: 337 - 337

17. Erratum to: Amyloid precursor-like protein 2 association with HLA class I molecules

    • Amit Tuli
    • Mahak Sharma
    • Joyce C. Solheim

    Erratum 13 October 2009 Pages: 339 - 339